Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$36.2M
5M shares
52-week range
$3.76 – $9.40
74% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
P/S (TTM)
0.4
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
www.harvardbioscience.comNo one on the platform currently holds HBIO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 101,427 | $493.9K |
| Execution date | Ratio |
|---|---|
| 2026-03-16 | 1-for-10reverse |
No one on the platform has traded HBIO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -8.1% | -3.3% | ||||
| Profit Margin % | -65.5% | -18.1% | -11.0% | |||
| Free Cash Flow Margin % | 6.5% | 2.9% | 3.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $90M | +4.5% | $-0.38 | $-0.38–$-0.38 | — | 1 |
| 2027 | $95M | +5.3% | $0.65 | $0.37–$0.92 | 12.3× | 2 |
| 2028 | $87M | -8.5% | $0.00 | $0.00–$0.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $-0.21 | $-0.14 | +33.3% |
| 2026-05-12 | $-0.62 | $-0.33 | +46.8% |
| 2026-03-12 | $0.04 | $-0.64 | -1700.0% |
| 2025-11-06 | $0.05 | $-0.28 | -652.0% |
| 2025-08-11 | $-0.25 | $-0.10 | +60.0% |
| 2025-05-12 | $-0.20 | $-0.10 | +50.0% |
| 2025-03-12 | $0.07 | $0.60 | +757.1% |
| 2024-11-07 | $0.15 | $-0.20 | -233.3% |
| $8M |
| — |
| NXGLNEXGEL, Inc. | $0.27 | +2.63% | $2M | — |
| NXLNexalin Technology, Inc. | $4.90 | -3.91% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
$HBIO lol seems I should have longer this instead of selling for just a 40% I would be up 80% now nuuu! Congrats gulls here
View on StockTwits ↗
$CVAT $HBIO $INBS $VATE $ZSQR The underlying deal is real — it’s in CVAT’s SEC filing — but the “10.8¢ locked in, 270% return” framing leaves out some key details. The offer price isn’t fixed: it’s calculated as Net Price ÷ shares outstanding, and that gets recalculated at a record date 45 business days after the tender offer even opens, so the final per-share number can still move. The deal also isn’t done — EGS needs at least 90% of shares tendered, plus a separate $7M side-deal for Alchemy Beverages has to close too. And this plays out over months, not days, with the offer staying open 60+ business days and another 30+ after final pricing is set. The gap between the 3-6¢ trading price and the 10¢+ deal price isn’t free money sitting on the table — it’s the market pricing in real risk that this doesn’t close cleanly. Legit news, just not the guaranteed windfall it’s being sold as.
View on StockTwits ↗
$CVAT Cavitation Technologies has execute a buyout for this company at 35 million $. This translate to 10.8c per share, you can finds this on the company SEC filing. The stock right now trades 3.9c, the buyout is for 10.8c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 10.8c Current sp: 3.9c 270% Return on Investment, Tender will start Monday!!!!!!!!!!!!!!!!!!!!!!!! https://www.compuserve.com/pf/story/0022/20260817/9811028.htm $VATE $INBS $ZSQR $HBIO
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-11-harvard-bioscience-inc-stock/ $HBIO Harvard Bioscience Earnings Transcript
View on StockTwits ↗
$HBIO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.64 down -28.00% YoY • Reported revenue of $22.73M up 11.13% YoY • Harvard Bioscience expects full-year 2026 revenue growth between 3% and 5%, with adjusted gross margin between 57% and 59% and adjusted EBITDA growth between 6% and 10% for the year.
View on StockTwits ↗
Harvard Bioscience, Inc. ($HBIO) Management Team presented today at the Sidoti Micro-Cap Virtual Conference. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_rfY5TakgRAa1dNVQpSknEA
View on StockTwits ↗Day 2: Presenting at 11:30am at the virtual #SidotiConference $HBIO $SKHRF http://dlvr.it/TSfbFd
View on StockTwits ↗$HBIO glad sold when I did. Was not a fan of this earnings. Increased debt was not what I wanted. It was a classic pump into earnings followed by a sell off. GL here though bulls
View on StockTwits ↗
$HBIO Share Price: $6.89 Contract Selected: Aug 21, 2026 $4.0 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.08 Potential Upside: 67% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-5-12-harvard-bioscience-inc-stock/ $HBIO Harvard Bioscience Earnings Transcript
View on StockTwits ↗$HBIO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.08 up 99.30% YoY • Reported revenue of $20.75M down -4.68% YoY • Harvard Bioscience reaffirms full-year 2026 guidance, anticipating revenue growth of 2% to 4%, adjusted gross margin of 58% to 60%, and adjusted EBITDA growth of 6% to 10%.
View on StockTwits ↗$HBIO I am outtie all. Taking my profits finally. The low volume and uptrend is kind of reminding me of another stock I didn’t sell, for it to just get halved by an offering by the company in seconds. Gl to all here and crush it.
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.